Liquidia (LQDA) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Liquidia (LQDA) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 87.0% versus a loss of 28.1%. Over five years, LQDA leads with a +1224.3% price change compared with +48.2% for PTCT. Liquidia is the larger company by market cap ($4.90 billion vs $4.71 billion), about 1.0 times the size.
On valuation, Liquidia trades at a lower forward P/E (15.1x vs 17.7x for PTC Therapeutics). PTC Therapeutics converts more of its revenue into profit, with a net margin of 39.4% versus -43.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LQDA | PTCT |
|---|---|---|
| Share price | $54.43 | $56.42 |
| Market cap | $4.90B | $4.71B |
| 1-day change | -3.88% | -3.27% |
| YTD return | +57.81% | -25.72% |
| 1-year return | +86.98% | -28.10% |
| 5-year return | +1224.33% | +48.24% |
| Forward P/E | 15.12 | 17.69 |
| EPS (TTM) | $-1.05 | $-1.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $158.32M | $1.73B |
| Revenue growth (YoY) | +1031.18% | +114.51% |
| Net income (latest FY) | $-68.92M | $682.64M |
| Operating margin | -32.45% | 50.09% |
| Net margin | -43.53% | 39.44% |
| 52-week high | $93.61 | $90.87 |
| 52-week low | $22.31 | $56.18 |
| Distance from 52-week high | -41.85% | -37.91% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +21.50% | +78.08% |
| Average volume | 3.52M | 1.07M |
| Shares outstanding | 90.11M | 83.54M |
| Employees | 216 | 991 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LQDA has outperformed PTCT by 115.1 percentage points over the past year.
- PTC Therapeutics is more profitable, keeping 39.4 cents of every revenue dollar as net income versus -43.5 cents for Liquidia.
- Liquidia grew revenue faster in its latest fiscal year (+1031.18% vs +114.51%).
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
LQDA vs PTCT FAQ
Which is bigger, Liquidia or PTC Therapeutics?
Liquidia (LQDA) is larger, with a market capitalization of $4.90B compared with $4.71B for PTC Therapeutics (PTCT).
Which stock has performed better over the past year, LQDA or PTCT?
LQDA returned +86.98% over the past 12 months, compared with -28.10% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are Liquidia and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.